Cagrilintide & Semaglutide

Reconstitution Steps

1. Use a sterile syringe to draw the validated diluent volume specified by the selected vial-format table, product label or approved laboratory method.
2. Inject the diluent slowly down the inside wall of the vial; avoid directing the stream onto the material and avoid foaming.
3. Gently swirl or roll until fully dissolved. Do not shake.
4. Label the vial with product, concentration, diluent, preparation date and operator; protect from light and refrigerate at 2–8 °C (35.6–46.4 °F) unless the product-specific method states otherwise.
5. Use within the product-specific validated hold time and no later than 4 weeks after preparation unless published stability data supports a different period.

Injection Technique

Use this technique only when the product-specific approved label or authorized research protocol specifies subcutaneous administration and trained personnel are responsible for the procedure.

• Clean the vial stopper and the selected administration site with alcohol; allow both surfaces to dry completely.
• Pinch a small fold of skin and insert the needle into the subcutaneous tissue at a 45–90° angle.
• Do not aspirate during a subcutaneous injection; deliver the validated volume slowly and steadily.
• If the approved protocol specifies a volume greater than 1.0 mL, divide it between separate sites rather than using one site.
• Rotate sites systematically; commonly referenced subcutaneous sites include the abdomen, thigh and upper arm.
• Wait several seconds after delivery before withdrawing the needle to help ensure the complete validated volume is delivered.
• Discard the used syringe immediately in an approved sharps container; never recap or reuse it.

Supplies Needed

• Product vial (Cagrilintide & Semaglutide; use the selected labelled vial strength).
• U-100 insulin syringe (1 mL capacity) or the sterile administration device specified by the approved protocol.
• Validated diluent in the container size specified by the product label or authorized preparation method.
• Alcohol swabs and an approved sharps container—use a fresh swab for the vial stopper and each administration site.

Storage Instructions

Proper storage helps maintain product quality and stability. The supplied label, COA and product-specific validated method take precedence over these general handling rules.

• Unopened: Keep the vial sealed, dry and protected from light at the temperature stated on the supplied label; do not assume a universal shelf life.
• After preparation: Refrigerate at 2–8 °C (35.6–46.4 °F) unless the product-specific method states otherwise, and use only within its validated in-use period.
• Before opening a cold vial, allow the sealed container to equilibrate as required by the method so condensation does not enter the product.
• Long-term storage: Freeze or aliquot only when supported by product-specific stability data; avoid repeated freeze–thaw cycles and discard material with unexpected particles, discoloration or container damage.

How This Works

Cagrilintide & Semaglutide combines a long-acting amylin analogue with a GLP-1 receptor agonist. Research evaluates whether complementary amylin and incretin signaling can influence satiation, gastric emptying, glucose regulation and body-weight outcomes.

Chemical identity or a proposed mechanism does not establish an effective amount, treatment indication or safe human-use protocol.

Benefits & Side Effects

Benefits

• No established clinical benefit: Research findings do not by themselves establish an approved indication, clinical benefit or appropriate human-use protocol.

Side Effects & Evidence Limits

• Benefits are not assumed: The existence of a product or study does not establish a clinical benefit.
• Adverse effects depend on identity and route: Risk cannot be generalized across peptide classes, molecular forms or preparations.
• Interactions and contraindications: These require official labeling or qualified clinical review where an approved medicine exists.
• Research-use limitation: Unapproved products may lack adequate human safety, pharmacokinetic and long-term outcome data.